This presentation will discuss the challenges of responding to the pandemic within the context of the vaccines eco-system and highlight the limitations and opportunities therein. It will also discuss Merck’s response to the pandemic, highlighting the different vaccine approaches, as well as the company’s response with antivirals and therapeutic treatments. With the success of new technologies, most notably mRNA, alternate approaches to pandemic response will also be discussed as well as its long-term impact on the vaccines market.